Exchange: NASDAQ·Updated 06:16 PM EDT
AKTX logo

AKTX Akari Therapeutics

$9.29
$0.60
(6.07%)
Today
Closed $9.29
$0.07
(0.75%)
After Hours
Mkt Cap$16.26M
Vol35,118.00

About AKTX

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.
52

Neutral Sentiment

How do you feel about AKTX?

BioResearcher
$AKTX This new data shows their drug can slow down tumor growth for those have already built resistance to current approved ADC drugs:
2
1
focafoca99
$AKTX discusses its differentiated PH1 ADC payload strategy and plans Phase 1 for AKTX-101 by mid-2027.
2
BioResearcher
$AKTX Big pharm are focusing on ADC because ADC will become standard of care for cancers: This recent article explains:
2
BioResearcher
$AKTX This new article explains why drug resistance has become a crisis for big pharma: and why big pharm are buying small ADC companies to address the resistance problems:
2
ABinterceptor
$AKTX Can anyone explain the trajectory of this stock? What are the catalysts? Thank you.
focafoca99
$AKTX amended its CEO agreement, boosting the chief's base salary to $625,000, raising bonus potential and granting RSUs and options.

Advertisement|Remove ads.